Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), CVS Health (CVS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immatics (IMTX – Research Report) and CVS Health (CVS – Research Report) with bullish sentiments.

Immatics (IMTX)

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Immatics yesterday and set a price target of $16.00. The company’s shares closed last Thursday at $11.60.

According to TipRanks.com, Stranahan is a 4-star analyst with an average return of 12.8% and a 60.4% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Recursion Pharmaceuticals, and Krystal Biotech.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immatics with a $20.50 average price target, an 86.4% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $25.00 price target.

See the top stocks recommended by analysts >>

CVS Health (CVS)

Bank of America Securities analyst Allen Lutz maintained a Buy rating on CVS Health yesterday and set a price target of $93.00. The company’s shares closed last Thursday at $66.80, close to its 52-week low of $66.34.

According to TipRanks.com, Lutz is a 3-star analyst with an average return of 3.0% and a 63.6% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, American Well, and Healthequity.

Currently, the analyst consensus on CVS Health is a Strong Buy with an average price target of $94.50, which is a 38.4% upside from current levels. In a report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $109.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IMTX:

• Immatics Announces Second Quarter 2023 Financial Results and Business Update
• Immatics initiates Phase 1/2 trial to evaluate PRAME TCR bispecific IMA402
• Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
• Immatics (NASDAQ:IMTX) Gains on Equity Infusion by Bristol-Myers Squibb (NYSE:BMY)
• Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb